IPSE Protein Modulation for Interstitial Cystitis Pain Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for interstitial cystitis and overactive bladder, such as opioids, have limited efficacy and are associated with significant side effects and addiction, while existing non-opioid alternatives like NSAIDs and anticonvulsants offer inadequate relief, highlighting a need for novel non-opioid analgesics that effectively target inflammation and pain.

Innovation Solution

Administration of the Interleukin-4-Inducing Principle of Schistosoma mansoni eggs (IPSE) protein or its derivatives, homologs, analogs, mutants, and mimics, which can be given intravenously or subcutaneously, to modulate bladder biology and reduce pain and inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If opioids are used to treat pain, then pain relief is achieved, but addiction and side effects occur

Engineering Contradiction:

Improvepain relief efficacyVSAvoidaddiction and side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies helminth therapy by introducing Schistosoma mansoni eggs or their derivatives (IPSE protein) to induce an anti-inflammatory immune response. This converts the harmful effect of inflammation into a beneficial therapeutic effect, where the parasite-derived molecules modulate the host immune system to reduce inflammation and pain without causing addiction

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The IPSE protein acts as an intermediary substance that mediates between the immune system and inflammatory pain. It induces IL-4 production and modulates immune responses, serving as a bridge that achieves pain relief through anti-inflammatory mechanisms without the direct harmful effects of opioids

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If NSAIDs and anticonvulsants are used as non-opioid alternatives, then addiction is avoided, but pain relief is inadequate

Engineering Contradiction:

Improveaddiction avoidanceVSAvoidpain relief efficacy

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent changes the therapeutic parameter from symptomatic pain management (NSAIDs/anticonvulsants) to targeting the underlying inflammatory mechanism. By using IPSE to modulate immune responses and reduce inflammation at its source, the treatment achieves superior pain relief while maintaining the non-addictive property of non-opioid approaches

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If corticosteroid injections are used to treat inflammation, then inflammation is reduced, but invasiveness and pain increase

Engineering Contradiction:

Improveinflammation reductionVSAvoidinvasiveness and procedural pain

Core Design Contradiction:

Object-affected harmful factorsVSEase of operation

Solution Approach 1:

The patent replaces the mechanical invasive approach of corticosteroid injections with a systemic immunomodulatory therapy. The IPSE protein or helminth eggs are administered to induce anti-inflammatory immune responses throughout the body, substituting mechanical injection with a biochemical mechanism that reduces inflammation without procedural invasiveness

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS11389507B2Use of interleukin-4-inducing principle of <i>Schistosoma mansoni </i>eggs for treating pain, interstitial cystitis and/or overactive bladder

Publication Date: 2022.07.19 BIOMEDICAL RES INST

AI summary

Methods are provided for the prevention and/or treatment of pain, interstitial cystitis and/or overactive bladder in a subject using an IPSE protein, such as H03 H-IPSE, H06 H-IPSE, M-IPSE or other IPSE homologs, variants, mutants or mimics. The IPSE protein can be administered prior to, contemporaneously with, and/or after the subject develops pain, interstitial cystitis and/or overactive bladder. Pharmaceutical compositions also are provided that contain one or more IPSE proteins in a pharmaceutically acceptable carrier, excipient or diluent.